Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

Sacituzumab goviteca provides clinically meaningful PFS benefit for hormone receptor HR+/HER2‐ advanced breast cancer patients

Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer

UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries

Understanding India’s compliance to the WHO Framework convention on tobacco control

War in Ukraine: Impacts on the Slovakian cancer care system

Inspiration Family: Challenges of the Ukrainian cancer charity on the frontline

War in Ukraine: Impacts on the Ukrainian cancer care system

War in Ukraine: Impacts on the Polish cancer care system and vaccination challenges

War in Ukraine: Current and future impacts on the Romanian cancer care system

Lymphoma Coalition: Challenges for Ukrainian haematological cancer patients